

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
*(Incorporated in Israel with limited liability)*  
**(Stock Code: 1696)**

**GRANT OF RESTRICTED SHARE UNITS PURSUANT TO  
THE 2021 RSU SCHEME**

On December 2, 2021, the Company granted restricted share units pursuant to the 2021 RSU Scheme to eligible participants, detailed of which are set out in this announcement.

Sisram Medical Ltd (the “**Company**”) refers to (i) the Company’s announcement dated September 9, 2021 and the Company’s circular dated October 25, 2021 (the “**Circular**”) and (ii) the poll results announcement of the extraordinary general meeting of the Company dated November 30, 2021 where Shareholders approved, among other things, the grant of a mandate to the directors of the Company (the “**Directors**”) to grant awards of restricted share units (the “**RSUs**”) to the Participants under the 2021 RSU Scheme. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The board of directors of the Company (the “**Board**”) announces that on December 2, 2021 (the “**Grant Date**”), pursuant to the 2021 RSU Scheme, the Company granted an aggregate of 3,716,060 RSUs, representing an aggregate of 3,716,060 Shares to a total 68 Participants (the “**Grantees**”), subject to acceptance by the Grantees. The RSUs will be vested in four equal instalments in a period of four years after the Grant Date. Of the 68 Grantees, two Grantees, namely, Mr. Yi LIU and Mr. Guojun BU, are connected persons of the Company and have been granted 220,000 RSUs and 80,000 RSUs, representing 220,000 Shares and 80,000 Shares, respectively.

As disclosed in the Circular, in accordance with the relevant Israeli laws and regulations, the Board has also approved the proposed grants of 800,000 RSUs and 183,490 RSUs to Mr. Lior Moshe DAYAN and Mr. Doron YANNAI, who are connected persons of the Company, and subject to the satisfaction of relevant conditions set out in the Circular, the effective date for the grants will be the date the EGM, being November 30, 2021. The Board announces that all conditions have been satisfied as at the date of this announcement and the grants of the RSUs to Mr. Lior Moshe DAYAN and Mr. Doron YANNAI have also been made.

Other than the grants to the connected persons set out above, none of the remaining Grantees is a director, chief executive or substantial shareholder of the Company or any of its subsidiaries, or any of their associates (as defined under the Listing Rules).

On behalf of the Board  
**Sisram Medical Ltd**  
復銳醫療科技有限公司\*  
**Yi LIU**  
*Chairman*

Hong Kong, December 2, 2021

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-Executive Directors.*

\* *for identification purpose only*